NEW YORK , Aug. 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming...
New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed...
Company to host conference call and webcast at 8:30 a.m. Eastern Time
First commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform
The financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investor
Contract award for over 100,000 eligible employees marks Dario's fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition management...
DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for Dario
Agreement representative of Dario's channel-led growth strategy to bring cardiometabolic digital health solution at scale to self-insured employers seeking measurable reductions in cardiometabolic risk...
Third health plan customer to expand beyond initial deployment, reinforcing Dario's land-and-expand strategy and creating significant opportunity to grow revenue within existing customer base
O'Reilly's extensive experience across healthcare compliance, risk management, regulatory oversight and payer operations expected to support Dario's continued expansion with health plans, employers and...